Suppr超能文献

带有亮氨酸拉链的模块化嵌合细胞因子受体通过 JAK/STAT 信号增强 CAR T 细胞的抗肿瘤活性。

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling.

机构信息

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.

Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Nat Biomed Eng. 2024 Apr;8(4):380-396. doi: 10.1038/s41551-023-01143-w. Epub 2023 Nov 30.

Abstract

The limited availability of cytokines in solid tumours hinders maintenance of the antitumour activity of chimeric antigen receptor (CAR) T cells. Cytokine receptor signalling pathways in CAR T cells can be activated by transgenic expression or injection of cytokines in the tumour, or by engineering the activation of cognate cytokine receptors. However, these strategies are constrained by toxicity arising from the activation of bystander cells, by the suboptimal biodistribution of the cytokines and by downregulation of the cognate receptor. Here we show that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provides optimal Janus kinase/signal transducer and activator of transcription signalling. Such chimeric cytokine receptors, which can be generated for common γ-chain receptors, interleukin-10 and -12 receptors, enabled T cells to survive cytokine starvation without induction of autonomous cell growth, and augmented the effector function of CAR T cells in vitro in the setting of chronic antigen exposure and in human tumour xenografts in mice. As a modular design, leucine zippers can be used to generate constitutively active cytokine receptors in effector immune cells.

摘要

实体肿瘤中细胞因子的有限可用性阻碍了嵌合抗原受体 (CAR) T 细胞抗肿瘤活性的维持。CAR T 细胞中的细胞因子受体信号通路可以通过在肿瘤中转基因表达或注射细胞因子、或通过工程化激活同源细胞因子受体来激活。然而,这些策略受到以下因素的限制:细胞因子的非最佳生物分布和同源受体下调导致的旁观者细胞激活毒性、毒性。在这里,我们表明,用两个亮氨酸拉链基序替换 T 细胞中异二聚体细胞因子受体的细胞外结构域,可提供最佳的 Janus 激酶/信号转导和转录激活因子信号。这种嵌合细胞因子受体可用于常见的 γ 链受体、白细胞介素-10 和 -12 受体,使 T 细胞能够在没有诱导自主细胞生长的情况下在细胞因子饥饿中存活,并在慢性抗原暴露的情况下增强 CAR T 细胞在体外的效应功能,并在小鼠的人肿瘤异种移植物中增强其效应功能。作为一种模块化设计,亮氨酸拉链可用于在效应免疫细胞中产生组成型激活的细胞因子受体。

相似文献

1
Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling.
Nat Biomed Eng. 2024 Apr;8(4):380-396. doi: 10.1038/s41551-023-01143-w. Epub 2023 Nov 30.
2
Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.
Cell Rep Med. 2024 May 21;5(5):101526. doi: 10.1016/j.xcrm.2024.101526. Epub 2024 Apr 25.
5
Interleukin-23 engineering improves CAR T cell function in solid tumors.
Nat Biotechnol. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3.
7
8
Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors.
Nat Biomed Eng. 2024 Dec;8(12):1592-1614. doi: 10.1038/s41551-024-01287-3. Epub 2024 Dec 23.
9
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
10

引用本文的文献

5
Deep insight into cytokine storm: from pathogenesis to treatment.
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
6
Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.
Nat Commun. 2025 Jan 29;16(1):1140. doi: 10.1038/s41467-025-56239-5.
7
ImmunOctoberfest reloaded.
Nat Immunol. 2025 Feb;26(2):165-167. doi: 10.1038/s41590-024-02069-4.
8
Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal.
Mol Ther. 2025 Feb 5;33(2):688-702. doi: 10.1016/j.ymthe.2024.12.014. Epub 2024 Dec 13.
9
10
Targeting systemic IL-2 to BCMA CAR-T cells.
Nat Immunol. 2024 Nov;25(11):1988-1990. doi: 10.1038/s41590-024-01993-9.

本文引用的文献

1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859.
2
Enhanced T cell effector activity by targeting the Mediator kinase module.
Science. 2022 Nov 11;378(6620):eabn5647. doi: 10.1126/science.abn5647.
3
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 9.
4
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
6
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.
Nat Biomed Eng. 2022 Feb;6(2):129-143. doi: 10.1038/s41551-021-00831-9. Epub 2022 Jan 10.
7
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
Sci Transl Med. 2021 Nov 17;13(620):eabh0272. doi: 10.1126/scitranslmed.abh0272.
9
Highly accurate protein structure prediction with AlphaFold.
Nature. 2021 Aug;596(7873):583-589. doi: 10.1038/s41586-021-03819-2. Epub 2021 Jul 15.
10
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Cell Rep Med. 2021 Jun 1;2(6):100297. doi: 10.1016/j.xcrm.2021.100297. eCollection 2021 Jun 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验